SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NTII - Miscellaneous
NTII 0.00010000.0%Nov 7 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy3/23/2005 7:36:41 AM
   of 1296
 
2005 - Effects of the NMDA receptor antagonist perzinfotel (EAA-090) on chemically-induced thermal hypersensitivity.

Brandt MR, Cummons TA, Potestio L, Sukoff SJ, Rosenzweig-Lipson S.

Neuroscience Discovery Research, Wyeth, Research.

Perzinfotel (EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid) is a selective, competitive NMDA receptor antagonist with high affinity for the glutamate site. The current study evaluated whether perzinfotel would have antinociceptive effects or block thermal hypersensitivity associated with the administration of chemical irritants in rats. Perzinfotel lacked antinociceptive effects but dose- and time-dependently blocked prostaglandin E2 (PGE2)- and capsaicin-induced thermal hypersensitivity in a warm-water tail withdrawal assay in rats. Doses of 10 mg/kg intraperitoneal (IP) or 100 mg/kg oral (PO) blocked PGE2-induced hypersensitivity by 60-80%. The magnitude of reversal was greater than other negative modulators of the NMDA receptor studied, such as un-competitive channel blockers (e.g., memantine, dizocilpine and ketamine), a NR2B selective antagonist (e.g., ifenprodil), and other glutamate antagonists (e.g., selfotel, CPP, CGP-39653), up to doses that suppressed operant rates of responding. In contrast to other negative modulators of the NMDA receptor studied, which typically decreased operant rates of responding at doses that lacked antinociceptive effects, perzinfotel did not modify response rates at doses that blocked irritant-induced thermal hypersensitivity. Collectively, these studies demonstrate that perzinfotel has therapeutic ratios for effectiveness versus adverse effects superior to those seen with other competitive and un-competitive NMDA receptor antagonists studied.

PMID: 15764736 [PubMed - as supplied by publisher]

ncbi.nlm.nih.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext